Cialis is a brand name of tadalafil, approved by the FDA in the following formulation(s):
CIALIS (tadalafil - tablet; oral)
Manufacturer: LILLY
Approval date: November 21, 2003
Strength(s): 10MG, 20MG [RLD], 5MG
Manufacturer: LILLY
Approval date: January 7, 2008
Strength(s): 2.5MG
Has a generic version of Cialis been approved?
No. There is currently no therapeutically equivalent version of Cialis available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cialis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Tetracyclic derivatives; process of preparation and use
Patent 5,859,006
Issued: January 12, 1999
Inventor(s): Daugan; Alain Claude-Marie
Assignee(s): ICOS Corporation
A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.Patent expiration dates:
- November 21, 2017✓✓
- November 21, 2017
Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
Patent 6,140,329
Issued: October 31, 2000
Inventor(s): Daugan; Alain Claude-Marie
Assignee(s): ICOS Corporation
The use of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-p yrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S 6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyhenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in methods and compositions for the treatment of impotence.Patent expiration dates:
- July 11, 2016✓✓
- July 11, 2016✓✓
- July 11, 2016
Beta-carboline drug products
Patent 6,821,975
Issued: November 23, 2004
Inventor(s): Neil R.; Anderson & Kerry J.; Hartauer & Martha A.; Kral & Gregory A.; Stephenson
Assignee(s): Lilly ICOS LLC
A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.Patent expiration dates:
- November 19, 2020✓✓✓
- November 19, 2020✓✓✓
- November 19, 2020✓✓✓
- November 19, 2020
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Patent 6,943,166
Issued: September 13, 2005
Inventor(s): Pullman; William Ernest & Whitaker; John Steven
Assignee(s): Lilly ICOS LLC.
The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.Patent expiration dates:
- April 26, 2020✓
- April 26, 2020✓
- April 26, 2020✓
- April 26, 2020
β-carboline pharmaceutical compositions
Patent 7,182,958
Issued: February 27, 2007
Inventor(s): Oren; Peter L. & Anderson; Neil R. & Kral; Martha A.
Assignee(s): Lilly Icos LLC.
Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use in treating sexual dysfunction, are disclosed.Patent expiration dates:
- April 26, 2020✓✓
- April 26, 2020✓✓
- April 26, 2020
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 7, 2011 - PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREAMTENT OF ERECTILE DYSFUNCTION
- October 6, 2014 - TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- October 6, 2014 - TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
See also...
- Cialis Consumer Information (Drugs.com)
- Cialis Consumer Information (Wolters Kluwer)
- Cialis Consumer Information (Cerner Multum)
- Cialis Advanced Consumer Information (Micromedex)
- Cialis AHFS DI Monographs (ASHP)
- Tadalafil Consumer Information (Drugs.com)
- Tadalafil Consumer Information (Wolters Kluwer)
- Tadalafil Consumer Information (Cerner Multum)
- Tadalafil Advanced Consumer Information (Micromedex)
- Tadalafil AHFS DI Monographs (ASHP)
No comments:
Post a Comment